Drugmakers raise 2018 U.S. prices, stick to self-imposed limits
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Allergen (AGN) PT Lowered to $203 at BofA/Merrill Lynch; 'Cost Restructuring Mitigates Near-Term Headwinds... $300M-400M in Net Savings for 2018E'
January 4, 2018 6:20 AM ESTBofA/Merrill Lynch lowered its price target on Allergen (NYSE: AGN) to $203.00 (from $204.00) while maintaining a Buy rating, following the company's announced cost-cutting measures for 2018.
Analyst Jason Gerberry notes a reduced price target on the shares, as the company announced cost-cutting measures for 2018,... More
Horizon Pharma (HZNP) PT Raised to $18 at Citi on 2018 Outlook; 'Remain Constructive... Stability in Primary Care Franchise'
January 4, 2018 6:12 AM ESTCiti raised its price target on Horizon Pharma (NASDAQ: HZNP) to $18.00 (from $16.00) while maintaining a Buy rating, following a review of the company's outlook into 2018.
Analyst Liav Abraham notes an increased price target on the shares following an updated outlook for 2018 remains constructive... More
